Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma

Trial Profile

Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Aldesleukin (Primary) ; Interferon beta (Primary) ; MCPyV TAg specific t cell vaccine (Primary)
  • Indications Merkel cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results assessing the augmentation of adoptive T-cell therapy in patients from two related phase I/II trials (NCT01758458 and NCT02584829; n=8), presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 01 Feb 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 23 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top